International Assets Investment Management LLC Sells 104 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

International Assets Investment Management LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.3% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,860 shares of the medical research company’s stock after selling 104 shares during the quarter. International Assets Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $1,029,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. GUNN & Co INVESTMENT MANAGEMENT INC. purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth about $253,000. Silver Oak Securities Incorporated acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $240,000. McAdam LLC acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $210,000. Choreo LLC grew its position in shares of Thermo Fisher Scientific by 109.8% during the 4th quarter. Choreo LLC now owns 3,354 shares of the medical research company’s stock valued at $1,781,000 after acquiring an additional 1,755 shares during the period. Finally, Kestra Private Wealth Services LLC raised its stake in shares of Thermo Fisher Scientific by 14.8% during the 4th quarter. Kestra Private Wealth Services LLC now owns 10,012 shares of the medical research company’s stock worth $5,314,000 after buying an additional 1,288 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.5 %

Shares of NYSE TMO opened at $614.82 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $622.30. The stock has a market capitalization of $234.86 billion, a price-to-earnings ratio of 39.44, a price-to-earnings-growth ratio of 2.82 and a beta of 0.77. The firm has a 50-day moving average price of $577.70 and a 200 day moving average price of $575.29. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The business had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. During the same quarter last year, the company earned $5.15 earnings per share. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be paid a dividend of $0.39 per share. The ex-dividend date is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Wall Street Analysts Forecast Growth

TMO has been the subject of several recent research reports. Barclays reduced their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a research note on Friday, June 28th. Royal Bank of Canada raised their price objective on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. Wells Fargo & Company began coverage on shares of Thermo Fisher Scientific in a report on Tuesday. They set an “overweight” rating and a $670.00 price objective on the stock. Finally, Stifel Nicolaus raised their price target on Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $630.41.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $1,201,700.00. Following the sale, the senior vice president now owns 13,083 shares in the company, valued at $7,860,920.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,238,340.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,084 shares of company stock worth $19,767,092. 0.34% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.